Yi‐Long Wu

Xihua University (CN)

Research Areas

Discover Papers by Yi‐Long Wu

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

134

Publications

2217

Citations

111302

i10-index

649

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary A...	2009	8196
The IASLC Lung Cancer Staging Project: Proposals f...	2016	4544
Erlotinib versus chemotherapy as first-line treatm...	2011	4075
Crizotinib versus Chemotherapy in Advanced <i>ALK<...	2013	3386
Lung cancer: current therapies and new targeted tr...	2016	3308
Pembrolizumab versus chemotherapy for previously u...	2019	3262
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> ...	2016	3255
First-Line Crizotinib versus Chemotherapy in <i>AL...	2014	3180
Afatinib versus cisplatin plus gemcitabine for fir...	2014	1960
Osimertinib in Resected <i>EGFR</i> -Mutated Non–S...	2020	1682

Publications

1.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Year: 2009Citations: 8196DOI: 10.1056/nejmoa0810699
2.
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Year: 2016Citations: 4544DOI: 10.1016/j.jtho.2015.09.009
3.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Year: 2011Citations: 4075DOI: 10.1016/s1470-2045(11)70184-x
4.
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Year: 2013Citations: 3386DOI: 10.1056/nejmoa1214886
5.
Lung cancer: current therapies and new targeted treatments
Year: 2016Citations: 3308DOI: 10.1016/s0140-6736(16)30958-8
6.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Year: 2019Citations: 3262DOI: 10.1016/s0140-6736(18)32409-7
7.
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Year: 2016Citations: 3255DOI: 10.1056/nejmoa1612674
8.
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Year: 2014Citations: 3180DOI: 10.1056/nejmoa1408440
9.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Year: 2014Citations: 1960DOI: 10.1016/s1470-2045(13)70604-1
10.
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Year: 2020Citations: 1682DOI: 10.1056/nejmoa2027071

About Yi‐Long Wu

Yi‐Long Wu is a researcher with 2217 publications and 111302 citations. They are affiliated with Xihua University. Their research focuses on . With an h-index of 134, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Yi‐Long Wu and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year